SCHEDULE: ADAR1 Capital Management Files Joint Ownership Statement

ADAR1 Capital Management and Daniel Schneeberger have filed a joint Schedule 13G, reporting beneficial ownership of 8.8% of Boundless Bio, Inc. common stock as of June 30, 2026.

Summary

• ADAR1 Capital Management, LLC and Daniel Schneeberger have entered into a joint filing agreement to report their beneficial ownership of Boundless Bio, Inc. common stock.
• As of June 30, 2026, the reporting persons collectively beneficially owned 1,968,216 shares of common stock.
• This ownership represents 8.8% of the total outstanding shares of Boundless Bio, Inc. common stock.
• The filing is made in accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934.
• The shares are owned directly by private investment funds managed by ADAR1 Capital Management, LLC.
• Daniel Schneeberger, as the sole manager of ADAR1 Capital Management, LLC, is deemed to indirectly beneficially own these shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a routine joint filing agreement for a Schedule 13G, indicating a change in beneficial ownership reporting rather than new operational or financial performance.

Positives

• Clear disclosure of beneficial ownership, providing transparency to the market.
• The filing indicates a significant but not controlling stake, suggesting a passive investment approach.

Negatives

• No new financial performance data or strategic updates are provided in this filing.

Risks

• Potential for future changes in beneficial ownership that could impact share price.
• The concentration of ownership could lead to increased volatility if positions are adjusted.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding future performance.

Management Comments

• ADAR1 Capital Management, LLC and Daniel Schneeberger certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant individual shareholders who acquire more than 5% of a company's outstanding equity. This filing confirms ADAR1 Capital Management's substantial investment in Boundless Bio, Inc., placing it among the larger shareholders.

Stakeholder Impact

• Shareholders gain transparency into significant beneficial ownership, aiding in understanding the company's shareholder base.
• The market receives confirmation of ADAR1 Capital Management's investment, which could influence investor sentiment.

Next Steps

• ADAR1 Capital Management, LLC and Daniel Schneeberger will continue to report any changes in beneficial ownership as required by SEC regulations.

Key Dates

Keywords

Beneficial Ownership, Schedule 13G, Joint Filing Agreement, Investment Management, Securities Ownership, Passive Investment